Article
Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience.
The American journal of gastroenterology - 1 Feb 2016
Pillai Anjana A, Wedd Joel, Norvell J P, Parekh Samir, Cheng Nicole, Young Nikita, Spivey James R, Ford Ryan
Abstract excerpt
OBJECTIVES: The combination of simeprevir (SMV) and sofosbuvir (SOF) was found to be well-tolerated with high sustained virologic response (SVR) rates in patients with genotype 1 chronic hepatitis C in clinical trials. Previous experience with hepatitis C virus (HCV) therapy has shown that patient tolerability and treatment efficacy described in controlled clinical trials did not necessarily mirror the "real...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.